Pricing Log in Create free account
Friday 6 November 2026 Export SYBX’s income statement to Excel — free account

Synlogic, Inc.

SYBX Healthcare Biotechnology

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023.

EPS
0.00%
Free cash flow
−277.9%

Quarter to June 2026, against a year earlier

1.10 0.10 +10.00%
Market cap
$6.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
3/9
Altman Z
−35.79
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 42.83%

Capital & Financial Ratios $m

Size
Market Cap 6.68
Revenue ttm 3.21
Net income ttm (0.65)
Free cash flow ttm (3.84)
Net debt Q (13.18)
Valuation
P/E 0.00
Forward P/E (2.80) (negative: loss-making)
Price / sales 4.26
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.14
Financial health
Current ratio Q 9.19 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (22.99)
Growth
Revenue growth Q −95.40% (below 0%: shrinking)
Operating income growth Q −30.24% (below 0%: shrinking)
EPS, this year +85.81% (at or above 15%: strong)
EPS, next year A +82.66% (at or above 15%: strong)
Revenue, next year A +55,875.00% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.1×, against a ten-year median of −2.0×; over the ten years it ranged from −42.6× in 2019 to 253× in 2018.
P/S against its own 10 years 8.90%
10-year low 10-year high
P/B against its own 10 years 62.37%
10-year low 10-year high
EV/Sales against its own 10 years 3.38%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 48 19 15 13
Receivables — — — —
Inventory — — — —
Other — 0 — —
50 20 15 13
2023 2024 2025 Q'26
Payables 1 0 0 0
ST’ Debt — — — —
Other — — — —
30 7 4 1

Compound Annual Growth %

10y 5y 3y
Sales — (67.55%) (83.42%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (17.88%) (36.53%) (47.63%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −0.13 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY24 −0.51 0.16 Beat by 0.67
Q3 FY24 −0.18 −0.01 Beat by 0.17
Q4 FY24 −0.10 −0.06 Beat by 0.04
Q2 FY25 −0.13 −0.04 Beat by 0.09

EPS $

Mar Jun Sep Dec Year
’26 0.05 (0.04) — — —
’25 0.03 (0.04) (0.19) 0.12 (0.08)
’24 (2.11) 0.25 (0.01) (0.06) (1.92)
’23 (3.45) (3.15) (2.57) (1.54) (9.42)
’22 (3.30) (3.30) (3.75) (3.60) (13.79)
’21 (5.40) (4.20) (4.35) (3.15) (16.34)
’20 (6.90) (6.60) (5.40) (5.85) (24.74)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 0 — — — 0
’23 0 0 0 3 3
’22 0 0 1 0 1
’21 — 0 1 1 2
’20 0 0 — 0 1
’19 0 0 0 1 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (2) 0 (1) (1) (4)
’24 (15) (15) (1) (1) (32)
’23 (22) (12) (13) (6) (52)
’22 (15) (14) (15) (12) (57)
’21 (14) (11) (14) (13) (52)
’20 (12) (9) (8) (10) (40)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (2) 0 (1) (1) (4)
’24 (16) (14) (1) (1) (30)
’23 (22) (12) (13) (6) (52)
’22 (16) (14) (16) (12) (58)
’21 (14) (11) (14) (13) (53)
’20 (13) (9) (8) (10) (40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 2 3 2 1 2 1 3 0 — 3 (39.5%) 23 — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 0.0 pt
EBT (21) (40) (48) (51) (59) (61) (66) (61) (23) (1) (1) (28.6%)
EBT margin, % (4,719.37) (1,652.09) (1,922.02) (2,309.94) (10,857.43) (3,452.74) (5,605.68) (1,817.24) (291,925.00) 0.00 0.00 +4,719.4 pt
Net income (21) (40) (48) (51) (59) (61) (66) (61) (23) (1) (1) (28.6%)
Per share, $
Per share, $ Revenue 4.22 5.45 1.58 1.10 0.23 0.48 0.25 0.52 0.00 0.00 0.00 n/m
Earnings (199.34) (89.95) (30.43) (25.49) (24.74) (16.34) (13.79) (8.81) (1.92) (0.08) (0.06) (58.1%)
Cash flow (194.18) (69.23) (26.66) (37.36) (16.55) (14.14) (11.90) (7.94) (2.60) (0.35) (0.31) (50.4%)
Capex (17.44) (5.72) (3.55) (0.62) (0.17) (0.18) (0.15) (0.03) 0.11 0.01 0.00 n/m
Free cash flow (211.62) (74.95) (30.21) (37.98) (16.71) (14.33) (12.05) (7.97) (2.49) (0.34) (0.31) (51.1%)
Book value 128.48 189.56 77.90 77.68 48.17 39.90 17.28 5.04 1.05 0.96 0.97 (41.9%)
Shares, m 0 0 2 2 2 4 5 7 12 12 12 +69.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.0
P/S 0.00 29.74 66.47 35.15 43.61 76.38 45.06 8.62 5.33 — 4.26 34.5
P/B 0.00 0.85 1.35 0.50 0.67 0.91 0.64 0.89 1.34 — 1.14 0.8
EV/Sales 0.00 (5.68) 17.85 (18.61) (1.53) 3.08 (20.72) (5.54) (0.56) — 0.15 (3.5)
EV/FCF (0.25) 0.41 (0.93) 0.54 0.07 (0.10) 0.42 0.36 0.06 — (0.13) 0.1
Cash, $m
Cash, $m Operating cash flow (20) (31) (42) (75) (40) (52) (57) (52) (32) (4) (4) (15.8%)
Capex (2) (3) (6) (1) 0 (1) (1) 0 1 0 0 n/m
Free cash flow (22) (34) (48) (77) (40) (53) (58) (52) (30) (4) (4) (16.9%)
Balance, $m
Balance, $m Working capital 12 80 116 124 99 123 68 20 13 12 12 (0.1%)
Net debt (14) (87) (123) (120) (80) (129) (78) (48) (19) (15) (13) +0.2%
Shareholders’ equity 14 85 124 157 115 147 83 33 13 12 12 (1.4%)
Returns, %
Returns, % ROA (37.77) (67.44) (40.36) (31.24) (35.60) (38.02) (46.32) (65.74) (48.98) (5.70) (4.25) +32.1 pt
ROIC 0.00 0.00 (2,027.79) (91.08) (108.09) (203.14) (845.27) 0.00 0.00 0.00 0.00 0.0 pt
ROE (77.09) (148.49) (46.32) (36.56) (43.50) (46.16) (57.55) (106.21) (102.63) (8.17) (5.32) +68.9 pt
People
People Employees 9 63 74 76 72 84 72 6 1 1 — (21.7%)
Revenue/emp, $m 0.05 0.04 0.03 0.03 0.01 0.02 0.02 0.56 0.01 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2024 · fundamentals updated 26 Oct 2026

Synlogic, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MTVA MetaVia Inc. $7.2M — (loss-making) — — n/m −22.42% (below 0%: shrinking) — 0.00% Compare
ENSC Ensysce Biosciences, Inc. $7.0M — (loss-making) — (loss-making) −15.10% (below 0%: shrinking) n/m +27.50% (above 0%: growing) 100.00% (221.28%) Compare
BCLI Brainstorm Cell Therapeutics Inc. $7.0M — (loss-making) — — n/m +74.44% (above 0%: growing) 0.00% 0.00% Compare
IMRN IMMURON $6.9M — (loss-making) — +757.00% (above 0%: growing) +12.00% (above 0%: growing) +42.55% (above 0%: growing) 72.16% 0.00% Compare
SYBX Synlogic, Inc. $6.7M — (loss-making) — (loss-making) −95.40% (below 0%: shrinking) n/m −277.87% (below 0%: shrinking) 100.00% 0.00%
KPRX Kiora Pharmaceuticals, Inc. $6.6M — (loss-making) — (loss-making) −93.64% (below 0%: shrinking) n/m +50.06% (above 0%: growing) 100.00% 0.00% Compare
FBLG FibroBiologics Inc. $6.4M — (loss-making) — — n/m +21.59% (above 0%: growing) — 0.00% Compare
ENVB Enveric Biosciences, Inc. $6.3M — (loss-making) — (loss-making) −7.28% (below 0%: shrinking) n/m −29.34% (below 0%: shrinking) 0.00% 0.00% Compare
APRE Aprea Therapeutics, Inc. $6.2M — (loss-making) — (loss-making) −98.40% (below 0%: shrinking) n/m −5.22% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $6.7M — — −15.10% — +24.55% 86.08% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 12 November 2025

Ownership

Directors and executive officers, together 2.62%
Funicular Funds 28.31%
New Enterprise Associates 24.98%
John A. Kryzanowski 6.27%
Bradley L. Radoff 5.38%
Armistice Capital LLC 5.25%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Synlogic, Inc. (SYBX) Latest News

30 Jul

Impact 5 · · hospitalmanagement.net
Impact 4 · · pharmaceutical-technology.com

29 Jul

Impact 5 · · InvestorsHub
Impact 4 ·

18 Sep

Impact 4 ·

12 Nov

Impact 3 ·

9 Aug

Impact 4 · · clinicaltrialsarena.com

8 Aug

Impact 3 · · GlobeNewswire

1 Aug

Impact 4 · · pharmaceutical-technology.com

23 May

Impact 4 · · InvestorPlace

14 May

Impact 4 · · GlobeNewswire

9 May

Impact 4 · · Simply Wall St.

19 Mar

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

20 Feb

Impact 4 · · GlobeNewswire

9 Feb

Impact 4 · · The Fly

8 Feb

Impact 4 · · GlobeNewswire

2 Feb

Impact 4 · · GlobeNewswire

16 Jan

Impact 3 · · ACCESSWIRE

4 Jan

Impact 4 · · GlobeNewswire

27 Dec

Impact 3 · · GlobeNewswire

7 Dec

Impact 4 · · GlobeNewswire

14 Nov

Impact 4 · · ACCESSWIRE

9 Nov

Impact 4 · · GuruFocus.com
Impact 4 · · GlobeNewswire

7 Nov

Impact 3 · · GlobeNewswire

2 Nov

Impact 4 · · Zacks

3 Oct

Impact 3 · · GlobeNewswire

29 Sep

Impact 4 · · GlobeNewswire

28 Sep

Impact 4 · · GlobeNewswire
stockrow.com/SYBX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com